A20

A20
Name	A20
Organism	Human
Length	790 aa (approx.)
Aliases	Tumor necrosis factor alpha-induced protein 3; OTU domain-containing protein 7B
Location	Chromosome 6

A20 is a ubiquitin-editing enzyme encoded by the TNFAIP3 locus implicated in modulation of inflammatory signaling, innate immunity, and cell death pathways. First identified as a transcriptional target of Tumor necrosis factor and studied in models including mouse and human cells, it functions at the intersection of ubiquitin metabolism, receptor signaling complexes, and transcriptional control. A20 has been linked to autoimmune syndromes, lymphoid malignancies, and inflammatory disorders studied by investigators in fields spanning immunology, rheumatology, and oncology.

Nomenclature and Identifiers

The protein is commonly referred to by the gene symbol TNFAIP3 and historically as Tumor necrosis factor alpha-induced protein 3 in literature from groups at National Institutes of Health and academic centers. Alternative names used in databases and experimental reports include the OTU family descriptor employed by proteomics groups at institutions such as Harvard University and Stanford University. Standard sequence identifiers map the human gene to chromosome 6 in assemblies curated by Ensembl, NCBI Gene, and UniProt. Clinical genetics consortia and genome-wide association studies coordinated by teams at Wellcome Trust and 23andMe reference common single-nucleotide polymorphisms in TNFAIP3 linked to disease susceptibility.

Structure and Biochemistry

A20 is a multi-domain protein with an N-terminal ovarian tumor (OTU) deubiquitinase domain characterized in structural studies from groups at European Molecular Biology Laboratory and Max Planck Institute. The C-terminal region contains multiple zinc finger motifs that mediate E3 ligase activity and ubiquitin-binding, analogous to domains characterized in proteins studied by researchers at Cold Spring Harbor Laboratory and Massachusetts Institute of Technology. High-resolution structures determined by teams at University of Cambridge and University of Oxford revealed catalytic residues conserved across species such as mouse, rat, and zebrafish. Biochemical assays published by laboratories at Johns Hopkins University and Yale University demonstrate cleavage specificity for K63- and linear-linked polyubiquitin chains and conjugation activities that generate K48-linked chains, integrating deubiquitinase and ubiquitin ligase functions within a single polypeptide.

Cellular Functions and Mechanisms

A20 operates at signaling nodes downstream of receptors studied by immunologists working with Toll-like receptor 4, Tumor necrosis factor receptor 1, and Interleukin-1 receptor systems. Cell biology groups at University of California, San Francisco and University College London have shown A20 is recruited to receptor proximal complexes containing adaptors such as TRAF6, RIPK1, and NEMO where it edits ubiquitin chains to terminate pro-inflammatory cascades. In innate immune cells analyzed by teams at Rockefeller University and Scripps Research, A20 limits activation of the NF-κB transcription factor and modulates programmed cell death pathways involving apoptosis and necroptosis. Proteomic studies from European Bioinformatics Institute and interactome mapping by Broad Institute identify A20 interactions with ubiquitin-conjugating enzymes including members of the UBC family and scaffold proteins implicated by research groups at Fred Hutchinson Cancer Center.

Role in Disease and Pathology

Genetic and clinical studies led by consortia at University of Oxford, Karolinska Institutet, and Cedars-Sinai Medical Center link TNFAIP3 variants to susceptibility for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, celiac disease, and type 1 diabetes. Somatic deletion or mutation of the locus is recurrent in lymphomas characterized by investigators at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center, including subsets of diffuse large B-cell lymphoma and Hodgkin lymphoma. Animal models developed at MIT and University of Pennsylvania demonstrate that loss of A20 function leads to uncontrolled inflammation, multiorgan pathology, and heightened sensitivity to endotoxin challenge utilized in studies by NIH-supported laboratories. Epidemiological analyses by teams at Imperial College London and Johns Hopkins Bloomberg School of Public Health correlate TNFAIP3 polymorphisms with clinical phenotypes and treatment responses.

Regulation and Signaling Pathways

Transcriptional induction of TNFAIP3 by NF-κB and other factors has been characterized in work from labs at UT Southwestern Medical Center and Columbia University. Post-translational regulation involves phosphorylation by kinases studied at Stanford and ubiquitination by E3 ligases described by researchers at Princeton University. A20 recruitment to signaling complexes depends on adaptor interactions with proteins such as TRAF2, MALT1, and ABIN1 as reported by groups at University of Toronto and McGill University. Crosstalk with pathways centered on IRAK4, TBK1, and IKK complex positions A20 as a feedback inhibitor that shapes responses to microbial products and cytokines investigated by teams at Pasteur Institute and Karolinska Institutet.

Therapeutic Targeting and Clinical Implications

Given its central role in inflammatory and neoplastic processes, A20 and its regulatory network are pursued as therapeutic targets by pharmaceutical groups at Roche, Novartis, and biotech startups emerging from Cambridge, Massachusetts incubators. Strategies include modulation of deubiquitinase activity, stabilization of protein interactions, and allele-specific approaches informed by clinical trials run by investigators at Mayo Clinic and Cleveland Clinic. Biomarker studies incorporating TNFAIP3 genotyping and expression profiling are being evaluated for patient stratification in trials for agents targeting TNF inhibitors, checkpoint blockade explored at MD Anderson Cancer Center, and small molecules affecting ubiquitin signaling pathways characterized at GlaxoSmithKline. Translational research networks at European Medicines Agency and Food and Drug Administration monitor implications for precision medicine and adverse-event risk associated with perturbation of A20-dependent pathways.

Category:Proteins